Akebia Therapeutics, Inc. (AKBA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 150M 300M 450M Q3 '21: 210M Q4 '21: 211.7M Q1 '22: 221M Q2 '22: 294.5M Q3 '22: 294.5M Q4 '22: 292.6M Q1 '23: 270.9M Q2 '23: 200.9M Q3 '23: 194.2M Q4 '23: 194.6M Q1 '24: 187.2M Q2 '24: 174.5M Q3 '24: 169.9M Q4 '24: 160.2M Q1 '25: 184.9M Q2 '25: 203.7M Q3 '25: 225.1M Q4 '25: 236.2M Q1 '26: 232.4M Q2 '26: 219.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 80M 160M 240M Q3 '21: 43.7M Q4 '21: 61M Q1 '22: 73.6M Q2 '22: 181M Q3 '22: 158.6M Q4 '22: 207.8M Q1 '23: 197.2M Q2 '23: 128.6M Q3 '23: 142.2M Q4 '23: 120.5M Q1 '24: 121.7M Q2 '24: 109.2M Q3 '24: 108.4M Q4 '24: 97M Q1 '25: 125.7M Q2 '25: 151.7M Q3 '25: 177.8M Q4 '25: 196.7M Q1 '26: 188.3M Q2 '26: 174.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '20: -376.4M Q1 '21: -382.3M Q2 '21: -287.8M Q3 '21: -284.6M Q4 '21: -264.5M Q1 '22: -259.1M Q2 '22: -145.7M Q3 '22: -141.2M Q4 '22: -80.8M Q1 '23: -46.8M Q2 '23: -89.9M Q3 '23: -52.5M Q4 '23: -46.3M Q1 '24: -35.6M Q2 '24: -35.3M Q3 '24: -34.8M Q4 '24: -50.5M Q1 '25: -22M Q2 '25: 791K Q3 '25: 17.7M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '20: -383.5M Q1 '21: -392.3M Q2 '21: -299.6M Q3 '21: -299.2M Q4 '21: -282M Q1 '22: -276M Q2 '22: -163.5M Q3 '22: -158M Q4 '22: -94.2M Q1 '23: -57.6M Q2 '23: -98.2M Q3 '23: -58.6M Q4 '23: -51.9M Q1 '24: -43M Q2 '24: -40.4M Q3 '24: -46M Q4 '24: -69.4M Q1 '25: -45.3M Q2 '25: -36.5M Q3 '25: -15.9M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Cost of Revenue TTM

0 60M 120M 180M Q3 '21: 166.3M Q4 '21: 150.7M Q1 '22: 147.4M Q2 '22: 113.5M Q3 '22: 135.9M Q4 '22: 84.8M Q1 '23: 73.6M Q2 '23: 72.3M Q3 '23: 52.1M Q4 '23: 74.1M Q1 '24: 65.6M Q2 '24: 65.3M Q3 '24: 61.5M Q4 '24: 63.2M Q1 '25: 59.2M Q2 '25: 52.1M Q3 '25: 47.3M Q4 '25: 39.5M Q1 '26: 44.1M Q2 '26: 44.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q3 '21: -220.9M Q4 '21: -253M Q1 '22: -203.8M Q2 '22: -171.4M Q3 '22: -81.3M Q4 '22: -73.2M Q1 '23: -69.1M Q2 '23: -34.8M Q3 '23: -75.8M Q4 '23: -23.4M Q1 '24: -25.3M Q2 '24: -39M Q3 '24: -38.5M Q4 '24: -40.7M Q1 '25: -34.8M Q2 '25: -2.4M Q3 '25: 32.4M Q4 '25: 68M Q1 '26: 60.4M Q2 '26: 41.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q3 '21: -221.3M Q4 '21: -253M Q1 '22: -204M Q2 '22: -171.5M Q3 '22: -81.4M Q4 '22: -73.3M Q1 '23: -69.1M Q2 '23: -34.8M Q3 '23: -75.8M Q4 '23: -23.4M Q1 '24: -25.3M Q2 '24: -39M Q3 '24: -38.5M Q4 '24: -40.7M Q1 '25: -34.9M Q2 '25: -2.6M Q3 '25: 32.2M Q4 '25: 67.7M Q1 '26: 60M Q2 '26: 40.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 100M 200M 300M Q3 '17: 46.9M Q4 '17: 49.7M Q3 '20: 143.3M Q1 '21: 153.8M Q2 '21: 161.3M Q3 '21: 173.8M Q1 '22: 179.6M Q2 '22: 190.4M Q3 '22: 183.9M Q1 '23: 184.8M Q2 '23: 186.8M Q3 '23: 188.3M Q1 '24: 205M Q2 '24: 209.7M Q3 '24: 210.3M Q1 '25: 241.6M Q2 '25: 271.1M Q3 '25: 274.4M Q1 '26: 267M Q2 '26: 269.6M Q4 '17 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.10 -1.40 -0.70 0.00 0.70 1.40 2.10 Q3 '21: -1.90 Q4 '21: -1.70 Q1 '22: -1.60 Q2 '22: -0.94 Q3 '22: -0.89 Q4 '22: -0.53 Q1 '23: -0.33 Q2 '23: -0.54 Q3 '23: -0.33 Q4 '23: -0.29 Q1 '24: -0.23 Q2 '24: -0.21 Q3 '24: -0.23 Q4 '24: -0.34 Q1 '25: -0.22 Q2 '25: -0.18 Q3 '25: -0.08 Q4 '25: -0.02 Q1 '26: -0.08 Q2 '26: -0.11 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.